Devyser Diagnostics AB
Research Devyser Diagnostics AB (DVYSR) on Bullrun: valuation model: 37.9% overvalued, market cap SEK 1.44B, P/E 96.0. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerDVYSR
- ExchangeST
- CountrySweden
- SectorHealthcare
- IndustryMedical Devices
- CurrencySEK
- Valuation signal37.9% overvalued
- Market capSEK 1.44B
- P/E96.0
- Financial periodQ1 2026
- RevenueSEK 61.80M
- Net incomeSEK 2.90M
- Free cash flow-SEK 600.00K
- Gross margin81.7%
Valuation Snapshot
Bullrun's latest valuation model marks Devyser Diagnostics AB as 37.9% overvalued; latest market cap is SEK 1.44B; P/E is 96.0.
About Devyser Diagnostics AB
Devyser Diagnostics AB (publ) provides diagnostic kits and advanced analysis services for clinical genetics and post-transplantation laboratories in Sweden, rest of Europe, the Middle East, and Africa. It offers kits and reagents, such as post-transplantation, thalassemia, fetal RHD screening NIPT, Cystic fibrosis cardiovascular diseases, male infertility, rapid aneuploidy analysis, accessories, hereditary cancer, and transfusion medicine products;
Frequently asked questions
Is Devyser Diagnostics AB overvalued or undervalued?
Bullrun's valuation model currently marks Devyser Diagnostics AB as 37.9% overvalued.
What is Devyser Diagnostics AB's market cap?
Devyser Diagnostics AB's market capitalization is SEK 1.44B.
What is Devyser Diagnostics AB's P/E ratio?
Devyser Diagnostics AB's price-to-earnings (P/E) ratio is 96.0.
What does Devyser Diagnostics AB do?
Devyser Diagnostics AB (publ) provides diagnostic kits and advanced analysis services for clinical genetics and post-transplantation laboratories in Sweden, rest of Europe, the Middle East, and Africa.